CN103830537A - Traditional Chinese medicinal composition for treating hypertension and preparation method thereof - Google Patents
Traditional Chinese medicinal composition for treating hypertension and preparation method thereof Download PDFInfo
- Publication number
- CN103830537A CN103830537A CN201410073835.XA CN201410073835A CN103830537A CN 103830537 A CN103830537 A CN 103830537A CN 201410073835 A CN201410073835 A CN 201410073835A CN 103830537 A CN103830537 A CN 103830537A
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- rhizoma
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of medicines, and discloses a traditional Chinese medicinal composition for treating hypertension. The traditional Chinese medicinal composition comprises the following raw materials in parts by weight: 21-67 parts of bighead atractylodes rhizome, 23-86 parts of notopterygium root, 31-78 parts of divaricate saposhnikovia root, 35-98 parts of magnolia officinalis, 22-56 parts of achyranthes bidentata, 33-89 parts of herba taxilli, 24-75 parts of rheum officinale, 26-51 parts of felwort, 34-102 parts of scutellaria baicalensis, 27-67 parts of dandelion, 15-46 parts of rush, 12-38 parts of radix scrophulariae, 18-49 parts of lily, 17-37 parts of day lily, 11-29 parts of costustoot, 18-48 parts of chrysanthemum, 16-37 parts of muskrootlike semiaquilegia root, and 10-30 parts of rhizoma acori graminei. After being combined, the medicinal materials are synergetic and compatible, so that the traditional Chinese medicinal composition has the effects of warming and invigorating kidney yang, activating blood circulation to remove stasis, reducing blood pressure and cholesterol, and preventing and treating atherosclerosis. The medicine has a good curative effect of reducing blood pressure in the clinical application process.
Description
Technical field
The present invention relates to medical technical field, relate in particular to one and be used for the treatment of hypertensive Chinese medicine composition and preparation method thereof.
Background technology
Hypertension is the disease that continues hyperpiesia, can cause the diseases such as apoplexy, heart disease, hemangioma, renal failure, hypertension is a kind of take arterial pressure rising as feature, can be functional with heart, blood vessel, brain and kidney and other organs or the systemic disease of organic change, it have essential hypertension and secondary hypertension point.The reason of hypertension incidence is a lot, can be divided into two aspects of h and E.Do not using in antihypertensive situation, systolic pressure >=139mmHg and/or diastolic pressure >=89mmHg, be divided into 1,2 by blood pressure level by hypertension, 3 grades.Systolic pressure >=140mmHg and diastolic pressure <90mmHg are single-row is isolated systolic hypertension.Patient previously has history of hypertension, is using at present antihypertensive, although blood pressure, lower than 140/90mmHg, also should be diagnosed as hypertension.
The traditional Chinese medical science is thought: hypertension pathogenesis is attacked in lung and the five internal organs by affection of exogenous wind-cold, strongly fragrant and heat-transformation, and the raw expectorant of fire-transformation, internal organs coelenteron stomach disorder due to wind pathogen cold syndrome, is absorbed poison by internal organs intracavity, produces Deficiency and coldness of spleen and stomach, intrathoracic distension, somatasthenia phenomenon.Food is assorted to be amassed in gastrointestinal mucosa, after absorption, can not normally mediate and absorb among the vital organs of the human body, blood flow, and liver and gall can not normally be mediated toxin, patient has fever, interior-heat, dry mouth and tougue, dark coloured urine, dizziness, lymph expansion, in lung, the pathogenesis of raw expectorant affects insufficiency of lung-QI, and blood flow just can not normally produce, and has reduced blood flow, produce hyperlipidemia, hyperglycemia, hypertension, because enteral film toxin produces, bring again the adverse effect of fatty liver to liver function.
Along with the change of growth in the living standard and rhythm of life, lipid in people's diet, alcohols are too much, are called as the rich and honour particularly commonly encountered diseases of more than 50 years old middle-aged and elderly people health of " three-hypers disease " (being hypertension, hyperglycemia and hyperlipidemia).The number of cardiovascular and cerebrovascular disease is died from every year up to 1,500 ten thousand people in the whole world, occupies various causes of the death first place.Cardiovascular and cerebrovascular disease has become " the No.1 killer " that mankind's Death causes is the highest, is also " the noiseless demon " of health of people.Cardiovascular and cerebrovascular disease has that " sickness rate is high, and mortality rate is high, and disability rate is high, and relapse rate is high, and complication is many, forms four high more than one features, and current China Patients with Cardiovascular/Cerebrovascular Diseases has exceeded 200,000,000 people.At present, there is the hypertensive chemicals of many treatments, although effect is fast, cure the symptoms, not the disease, also can medicine be produced and be relied on, and also have certain side effect, undesirable for patient.
Summary of the invention
Not very desirable problem in order to solve current high blood pressure disease treatment situation, the invention provides one and be used for the treatment of hypertensive Chinese medicine composition.
The technical scheme that the present invention takes is:
Of the present inventionly be used for the treatment of hypertensive Chinese medicine composition and formed by the raw material of following weight portion: Rhizoma Atractylodis Macrocephalae 21-67, Rhizoma Et Radix Notopterygii 23-86, Radix Saposhnikoviae 31-78, Cortex Magnoliae Officinalis 35-98, Radix Achyranthis Bidentatae 22-56, Herba Taxilli 33-89, Radix Et Rhizoma Rhei 24-75, Radix Gentianae 26-51, Radix Scutellariae 34-102, Herba Taraxaci 27-67, Medulla Junci 15-46, Radix Scrophulariae 12-38, Bulbus Lilii 18-49, Flos Hemerocallis 17-37, Radix Aucklandiae 11-29, Flos Chrysanthemi 18-48, Radix Semiaquilegiae 16-37, Rhizoma Acori Graminei 10-30.
Preferred: described Chinese medicine composition is made up of the raw material of following weight portion: Rhizoma Atractylodis Macrocephalae 30-50, Rhizoma Et Radix Notopterygii 35-65, Radix Saposhnikoviae 42-63, Cortex Magnoliae Officinalis 46-77, Radix Achyranthis Bidentatae 34-46, Herba Taxilli 50-72, Radix Et Rhizoma Rhei 36-60, Radix Gentianae 31-45, Radix Scutellariae 55-89, Herba Taraxaci 32-53, Medulla Junci 25-31, Radix Scrophulariae 23-34, Bulbus Lilii 20-40, Flos Hemerocallis 21-30, Radix Aucklandiae 18-23, Flos Chrysanthemi 22-35, Radix Semiaquilegiae 21-32, Rhizoma Acori Graminei 15-25.
As one of preferred technical scheme: described Chinese medicine composition is made up of the raw material of following weight portion: the Rhizoma Atractylodis Macrocephalae 30, Rhizoma Et Radix Notopterygii 65, Radix Saposhnikoviae 42, Cortex Magnoliae Officinalis 77, Radix Achyranthis Bidentatae 34, Herba Taxilli 72, Radix Et Rhizoma Rhei 36, Radix Gentianae 45, Radix Scutellariae 55, Herba Taraxaci 53, Medulla Junci 25, Radix Scrophulariae 34, Bulbus Lilii 20, Flos Hemerocallis 30, the Radix Aucklandiae 18, Flos Chrysanthemi 35, Radix Semiaquilegiae 21, Rhizoma Acori Graminei 25.
As one of preferred technical scheme: described Chinese medicine composition is made up of the raw material of following weight portion: the Rhizoma Atractylodis Macrocephalae 50, Rhizoma Et Radix Notopterygii 35, Radix Saposhnikoviae 63, Cortex Magnoliae Officinalis 46, Radix Achyranthis Bidentatae 46, Herba Taxilli 50, Radix Et Rhizoma Rhei 60, Radix Gentianae 31, Radix Scutellariae 89, Herba Taraxaci 32, Medulla Junci 31, Radix Scrophulariae 23, Bulbus Lilii 40, Flos Hemerocallis 21, the Radix Aucklandiae 23, Flos Chrysanthemi 22, Radix Semiaquilegiae 32, Rhizoma Acori Graminei 15.
As one of preferred technical scheme: described Chinese medicine composition is made up of the raw material of following weight portion: the Rhizoma Atractylodis Macrocephalae 40, Rhizoma Et Radix Notopterygii 55, Radix Saposhnikoviae 54, Cortex Magnoliae Officinalis 62, Radix Achyranthis Bidentatae 41, Herba Taxilli 63, Radix Et Rhizoma Rhei 50, Radix Gentianae 39, Radix Scutellariae 69, Herba Taraxaci 44, Medulla Junci 28, Radix Scrophulariae 30, Bulbus Lilii 30, Flos Hemerocallis 25, the Radix Aucklandiae 20, Flos Chrysanthemi 29, Radix Semiaquilegiae 27, Rhizoma Acori Graminei 20.
The dosage form that is used for the treatment of hypertensive Chinese medicine composition of the present invention is decoction, tablet, granule, pill, capsule or injection.
Of the present inventionly be used for the treatment of hypertensive Chinese medicine composition and can be used for the treatment of hypertension and complication thereof.
Of the present inventionly be used for the treatment of hypertensive Chinese medicine to make the method for decoction as follows:
(1) first get the raw material of medicine of the present invention, remove wherein impurity, then clean sterilizing;
(2) then take raw material by proportioning, after drying, use cracker for medicine respectively by raw material pulverizing, and mistake 80 mesh sieves, then after the powder of all raw materials being mixed, add water to the 5-10 of medicine gross weight doubly, then decoct 2-4h, filter, in medicinal residues, add medicine gross weight 1-3 water doubly again, after decoction 2h, filter waste, the filtrate after twice filtration is decoction prepared by the present invention.
The present invention is by after said medicine combination, and between each medical material, collaborative compatibility, makes it have warming and recuperating the kidney-YANG, blood circulation promoting and blood stasis dispelling, reduces blood pressure, and cholesterol, prevents and treats atherosclerotic effect.Medicine of the present invention has the curative effect of good blood pressure lowering in process of clinical application.
The specific embodiment
The following examples are to describe in further detail of the present invention.
Embodiment 1
1.1 raw material compositions (g):
The Rhizoma Atractylodis Macrocephalae 21, Rhizoma Et Radix Notopterygii 86, Radix Saposhnikoviae 31, Cortex Magnoliae Officinalis 98, Radix Achyranthis Bidentatae 22, Herba Taxilli 89, Radix Et Rhizoma Rhei 24, Radix Gentianae 51, Radix Scutellariae 34, Herba Taraxaci 67, Medulla Junci 15, Radix Scrophulariae 38, Bulbus Lilii 18, Flos Hemerocallis 37, the Radix Aucklandiae 11, Flos Chrysanthemi 48, Radix Semiaquilegiae 16, Rhizoma Acori Graminei 30.
1.2 preparation methoies:
(1) first get the raw material of medicine of the present invention, remove wherein impurity, then clean sterilizing;
(2) then take raw material by proportioning, after drying, use cracker for medicine respectively by raw material pulverizing, and mistake 80 mesh sieves, then after the powder of all raw materials being mixed, add water to 5 times of medicine gross weight, then decoct 2h, filter, in medicinal residues, add the water of 1 times of medicine gross weight again, after decoction 2h, filter waste, the filtrate after twice filtration is decoction prepared by the present invention.
Embodiment 2
2.1 raw material compositions (g):
The Rhizoma Atractylodis Macrocephalae 67, Rhizoma Et Radix Notopterygii 23, Radix Saposhnikoviae 78, Cortex Magnoliae Officinalis 35, Radix Achyranthis Bidentatae 56, Herba Taxilli 33, Radix Et Rhizoma Rhei 75, Radix Gentianae 26, Radix Scutellariae 102, Herba Taraxaci 27, Medulla Junci 46, Radix Scrophulariae 12, Bulbus Lilii 49, Flos Hemerocallis 17, the Radix Aucklandiae 29, Flos Chrysanthemi 18, Radix Semiaquilegiae 37, Rhizoma Acori Graminei 10.
2.2 preparation methoies:
(1) first get the raw material of medicine of the present invention, remove wherein impurity, then clean sterilizing;
(2) then take raw material by proportioning, after drying, use cracker for medicine respectively by raw material pulverizing, and mistake 80 mesh sieves, then after the powder of all raw materials being mixed, add water to 10 times of medicine gross weight, then decoct 4h, filter, in medicinal residues, add the water of 3 times of medicine gross weights again, after decoction 2h, filter waste, the filtrate after twice filtration is decoction prepared by the present invention.
Embodiment 3
3.1 raw material compositions (g):
The Rhizoma Atractylodis Macrocephalae 30, Rhizoma Et Radix Notopterygii 65, Radix Saposhnikoviae 42, Cortex Magnoliae Officinalis 77, Radix Achyranthis Bidentatae 34, Herba Taxilli 72, Radix Et Rhizoma Rhei 36, Radix Gentianae 45, Radix Scutellariae 55, Herba Taraxaci 53, Medulla Junci 25, Radix Scrophulariae 34, Bulbus Lilii 20, Flos Hemerocallis 30, the Radix Aucklandiae 18, Flos Chrysanthemi 35, Radix Semiaquilegiae 21, Rhizoma Acori Graminei 25.
3.2 preparation methoies:
(1) first get the raw material of medicine of the present invention, remove wherein impurity, then clean sterilizing;
(2) then take raw material by proportioning, after drying, use cracker for medicine respectively by raw material pulverizing, and mistake 80 mesh sieves, then after the powder of all raw materials being mixed, add water to 8 times of medicine gross weight, then decoct 3h, filter, in medicinal residues, add the water of 2 times of medicine gross weights again, after decoction 2h, filter waste, the filtrate after twice filtration is decoction prepared by the present invention.
Embodiment 4
4.1 raw material compositions (g):
The Rhizoma Atractylodis Macrocephalae 50, Rhizoma Et Radix Notopterygii 35, Radix Saposhnikoviae 63, Cortex Magnoliae Officinalis 46, Radix Achyranthis Bidentatae 46, Herba Taxilli 50, Radix Et Rhizoma Rhei 60, Radix Gentianae 31, Radix Scutellariae 89, Herba Taraxaci 32, Medulla Junci 31, Radix Scrophulariae 23, Bulbus Lilii 40, Flos Hemerocallis 21, the Radix Aucklandiae 23, Flos Chrysanthemi 22, Radix Semiaquilegiae 32, Rhizoma Acori Graminei 15.
4.2 preparation methoies:
Preparation method is with 3.2 of embodiment 3.
Embodiment 5
5.1 raw material compositions (g): the Rhizoma Atractylodis Macrocephalae 40, Rhizoma Et Radix Notopterygii 55, Radix Saposhnikoviae 54, Cortex Magnoliae Officinalis 62, Radix Achyranthis Bidentatae 41, Herba Taxilli 63, Radix Et Rhizoma Rhei 50, Radix Gentianae 39, Radix Scutellariae 69, Herba Taraxaci 44, Medulla Junci 28, Radix Scrophulariae 30, Bulbus Lilii 30, Flos Hemerocallis 25, the Radix Aucklandiae 20, Flos Chrysanthemi 29, Radix Semiaquilegiae 27, Rhizoma Acori Graminei 20.
5.2 preparation methoies:
Preparation method is with 3.2 of embodiment 3.
Clinical efficacy:
1.1 MethodsThe cases enrolled diagnostic criterias
At present domestic hypertensive diagnosis adopts the standard of Chinese Treatment Guidelines for Hypertension suggestion in 2000:
While adhering to different ranks separately as patient's systolic pressure and diastolic pressure, be as the criterion with higher grade scale.
1.2 exclusion standard
Get rid of gestation, women breast-feeding their children, allergic constitution; Get rid of severe cardiac dysfunction, psychotic.
1.3 physical data
All selected patients are divided into two groups at random, treatment group 198 examples, wherein male patient's 98 examples, female patient 100 examples; Mild hypertension patient 20 examples, moderate hypertension patient 89 examples, severe hypertension patient 89 examples; Matched group 125 examples, wherein male patient's 56 examples, female patient 69 examples; Mild hypertension patient 12 examples, moderate hypertension patient 53 examples, severe hypertension patient 60 examples.Two groups of Genders, ill degree, through the equal not statistically significant of comparing difference (P > 0.05), have comparability.
1.4 Therapeutic Method
1.4.1 treatment group is taken decoction prepared by the embodiment of the present invention 5, instructions of taking: once get pharmaceutical composition 20g of the present invention, make the decoction of 50-150ml, after half an hour after meal, take, one day twice, sooner or later take, take continuously 30 days, during medication, avoid pungent, greasy.
1.4.2 the oral Norvasc of matched group (Amlodipine Besylate Tablet),, every day 1 time, takes 30 days continuously by each 1.
1.5 therapeutic outcome
Two groups of therapeutic outcomes are as shown in table 1.
Table 1 liang group therapeutic effect contrast
| Group | Number of cases | Normal arterial pressure | Normal high value | 1 grade of hypertension |
| Treatment group | 198 | 183 | 12 | 3 |
| Matched group | 125 | 98 | 18 | 9 |
1.6 untoward reaction
In treatment group, there are 8 examples to occur the slight symptom of feeling sick, but do not affect continual cure; In matched group, there are 16 examples to occur headache symptom, wherein have 9 examples to abandon continual cure.
1.7 conclusion
From the above results, medicine of the present invention is obviously better than Norvasc aspect curative effect, and the adverse reaction rate of medicine of the present invention still less, and patient's compliance is better.
Model case:
Case 1
Zhang, man, 42 years old, Dongguan, Guangdong people, diagnosis suffers from hypertension 5 years, take Western medicine blood pressure lowering before taking Drug therapy of the present invention, but effect is always not good always, blood pressure repeatedly always, but also often uncomfortable in chest, the migraine of self-induction, cannot be engaged in normal work.Take this Chinese medicine after 30 days, malaise symptoms disappears, and blood pressure returns to normal level, and never repeatedly, can normally work now.
Case 2
Shen, female, 67 years old, people from Pingxiang Jiangxi, diagnosis suffers from hypertension and has 15 years, once takes multiple Western medicine, Chinese medicine and folk prescription among the people before taking Drug therapy of the present invention, and all invalid, before treatment, blood pressure is 183/114mmHg.Before treatment patient have uncomfortable in chest, left ventricle pain, headache, symptom.Take Chinese medicine of the present invention after 30 days, former malaise symptoms disappears, and Blood pressure drop, to 130/88mmHg, continues again to take medicine after 30 days, and Blood pressure drop, to 118/76mmHg, does not after this recur.
Case 3
Hao, man, 62 years old, people from Qiqihar, Heilungkiang, diagnosis suffers from hypertension more than 10 years, and with hyperlipidemia, takes blood pressure lowering, fat-reducing medicament always, but produces little effect, and before treatment, blood pressure is 169/105mmHg.Normal sense is nervous, dizzy, insomnia.Take Chinese medicine of the present invention after 30 days, former malaise symptoms disappears, and Blood pressure drop is to 111/79mmHg, and hyperlipidemia also returns to normal level, cholesterol 4.48, liver oil three fat 1.76.
Although illustrated and described embodiments of the invention, for the ordinary skill in the art, be appreciated that without departing from the principles and spirit of the present invention and can carry out multiple variation, modification, replacement and modification to these embodiment, scope of the present invention is limited by claims and equivalent thereof.
Claims (9)
1. be used for the treatment of a hypertensive Chinese medicine composition, it is characterized in that: described Chinese medicine composition is made up of the raw material of following weight portion: Rhizoma Atractylodis Macrocephalae 21-67, Rhizoma Et Radix Notopterygii 23-86, Radix Saposhnikoviae 31-78, Cortex Magnoliae Officinalis 35-98, Radix Achyranthis Bidentatae 22-56, Herba Taxilli 33-89, Radix Et Rhizoma Rhei 24-75, Radix Gentianae 26-51, Radix Scutellariae 34-102, Herba Taraxaci 27-67, Medulla Junci 15-46, Radix Scrophulariae 12-38, Bulbus Lilii 18-49, Flos Hemerocallis 17-37, Radix Aucklandiae 11-29, Flos Chrysanthemi 18-48, Radix Semiaquilegiae 16-37, Rhizoma Acori Graminei 10-30.
2. be as claimed in claim 1ly used for the treatment of hypertensive Chinese medicine composition, it is characterized in that: described Chinese medicine composition is made up of the raw material of following weight portion: Rhizoma Atractylodis Macrocephalae 30-50, Rhizoma Et Radix Notopterygii 35-65, Radix Saposhnikoviae 42-63, Cortex Magnoliae Officinalis 46-77, Radix Achyranthis Bidentatae 34-46, Herba Taxilli 50-72, Radix Et Rhizoma Rhei 36-60, Radix Gentianae 31-45, Radix Scutellariae 55-89, Herba Taraxaci 32-53, Medulla Junci 25-31, Radix Scrophulariae 23-34, Bulbus Lilii 20-40, Flos Hemerocallis 21-30, Radix Aucklandiae 18-23, Flos Chrysanthemi 22-35, Radix Semiaquilegiae 21-32, Rhizoma Acori Graminei 15-25.
3. be as claimed in claim 1ly used for the treatment of hypertensive Chinese medicine composition, it is characterized in that: described Chinese medicine composition is made up of the raw material of following weight portion: the Rhizoma Atractylodis Macrocephalae 30, Rhizoma Et Radix Notopterygii 65, Radix Saposhnikoviae 42, Cortex Magnoliae Officinalis 77, Radix Achyranthis Bidentatae 34, Herba Taxilli 72, Radix Et Rhizoma Rhei 36, Radix Gentianae 45, Radix Scutellariae 55, Herba Taraxaci 53, Medulla Junci 25, Radix Scrophulariae 34, Bulbus Lilii 20, Flos Hemerocallis 30, the Radix Aucklandiae 18, Flos Chrysanthemi 35, Radix Semiaquilegiae 21, Rhizoma Acori Graminei 25.
4. be as claimed in claim 1ly used for the treatment of hypertensive Chinese medicine composition, it is characterized in that: described Chinese medicine composition is made up of the raw material of following weight portion: the Rhizoma Atractylodis Macrocephalae 50, Rhizoma Et Radix Notopterygii 35, Radix Saposhnikoviae 63, Cortex Magnoliae Officinalis 46, Radix Achyranthis Bidentatae 46, Herba Taxilli 50, Radix Et Rhizoma Rhei 60, Radix Gentianae 31, Radix Scutellariae 89, Herba Taraxaci 32, Medulla Junci 31, Radix Scrophulariae 23, Bulbus Lilii 40, Flos Hemerocallis 21, the Radix Aucklandiae 23, Flos Chrysanthemi 22, Radix Semiaquilegiae 32, Rhizoma Acori Graminei 15.
5. be as claimed in claim 1ly used for the treatment of hypertensive Chinese medicine composition, it is characterized in that: described Chinese medicine composition is made up of the raw material of following weight portion: the Rhizoma Atractylodis Macrocephalae 40, Rhizoma Et Radix Notopterygii 55, Radix Saposhnikoviae 54, Cortex Magnoliae Officinalis 62, Radix Achyranthis Bidentatae 41, Herba Taxilli 63, Radix Et Rhizoma Rhei 50, Radix Gentianae 39, Radix Scutellariae 69, Herba Taraxaci 44, Medulla Junci 28, Radix Scrophulariae 30, Bulbus Lilii 30, Flos Hemerocallis 25, the Radix Aucklandiae 20, Flos Chrysanthemi 29, Radix Semiaquilegiae 27, Rhizoma Acori Graminei 20.
6. as described in claim 1-5 any one, be used for the treatment of hypertensive Chinese medicine composition, it is characterized in that: the dosage form of described Chinese medicine is decoction, pill, tablet, granule, capsule or injection.
7. as described in claim 1-5 any one, be used for the treatment of hypertensive Chinese medicine composition, it is characterized in that: the dosage form of described Chinese medicine is decoction.
8. a method of preparing Chinese medicine composition as claimed in claim 7, is characterized in that: the concrete steps of described method are as follows:
(1) first get the raw material of medicine of the present invention, remove wherein impurity, then clean sterilizing;
(2) then take raw material by proportioning, after drying, use cracker for medicine respectively by raw material pulverizing, and mistake 80 mesh sieves, then after the powder of all raw materials being mixed, add water to the 5-10 of medicine gross weight doubly, then decoct 2-4h, filter, in medicinal residues, add medicine gross weight 1-3 water doubly again, after decoction 2h, filter waste, the filtrate after twice filtration is decoction prepared by the present invention.
9. as described in claim 1-5 any one, be used for the treatment of the purposes of hypertensive Chinese medicine composition in treatment hypertension and complication thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410073835.XA CN103830537A (en) | 2014-02-28 | 2014-02-28 | Traditional Chinese medicinal composition for treating hypertension and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410073835.XA CN103830537A (en) | 2014-02-28 | 2014-02-28 | Traditional Chinese medicinal composition for treating hypertension and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103830537A true CN103830537A (en) | 2014-06-04 |
Family
ID=50794639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410073835.XA Pending CN103830537A (en) | 2014-02-28 | 2014-02-28 | Traditional Chinese medicinal composition for treating hypertension and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103830537A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104605345A (en) * | 2015-01-08 | 2015-05-13 | 张鹏宴 | Healthcare food containing lactobacillus paracasei for treatment of hyperlipidemia |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101244172A (en) * | 2008-03-27 | 2008-08-20 | 谷瑞兴 | Chinese medicine for treating hypertension |
-
2014
- 2014-02-28 CN CN201410073835.XA patent/CN103830537A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101244172A (en) * | 2008-03-27 | 2008-08-20 | 谷瑞兴 | Chinese medicine for treating hypertension |
Non-Patent Citations (2)
| Title |
|---|
| 史连和等: "中医药治疗高血压病进展", 《内蒙古民族大学学报(自然科学版)》 * |
| 史连和等: "中医药治疗高血压病进展", 《内蒙古民族大学学报(自然科学版)》, vol. 18, no. 3, 30 June 2003 (2003-06-30), pages 277 - 282 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104605345A (en) * | 2015-01-08 | 2015-05-13 | 张鹏宴 | Healthcare food containing lactobacillus paracasei for treatment of hyperlipidemia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103463609A (en) | Traditional Chinese medicine oral decoction for treating upper respiratory infection and preparation method for Chinese patent medicine of traditional Chinese medicine oral decoction | |
| CN103877263B (en) | A kind of antifatigue health preparation of the compound Chinese medicine such as red ginseng, maca, green-tea extract (theanine) | |
| CN102526474B (en) | Chinese medicine composition for treating neurasthenia | |
| CN102166278B (en) | Chinese medicinal composition for treating pediatric rheumatoid arthritis and preparation method thereof | |
| CN104189789A (en) | Traditional Chinese medicine composition for treating acute infectious jaundice type hepatitis | |
| CN101095768B (en) | Chinese traditional medicine capsule for treating primary hypertension for persons in middle and old age | |
| CN104547496A (en) | Traditional Chinese medicine composition for moistening lung to arrest cough and preparation method thereof | |
| CN104757669A (en) | Blood pressure and blood lipid lowering health drink and preparation method thereof | |
| CN102283956B (en) | Orally administered drug for treating chronic hepatitis | |
| CN103301267A (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
| CN103623280A (en) | Traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases | |
| CN104225425A (en) | Chinese herbal preparation for enhancing immunity, improving sleep and preventing cardio-cerebrovascular disease, and preparation method thereof | |
| CN103536849A (en) | Drug for treating pulmonary embolism and preparation method thereof | |
| CN104324134B (en) | One kind improves microcirculatory Chinese medicine composition and preparation method thereof | |
| CN103830537A (en) | Traditional Chinese medicinal composition for treating hypertension and preparation method thereof | |
| CN104800772A (en) | Traditional Chinese medicine composition for treating vital-energy-depression type coronary heart disease and application of traditional Chinese medicine composition | |
| CN101637558B (en) | Medicament for treating thrombocytolytic purpura | |
| CN105126034A (en) | Pharmaceutical preparation for treating coronary heart disease | |
| CN100502925C (en) | Antihyperglycemic hepatoprotective agent and its preparation method | |
| CN103212044A (en) | Traditional Chinese medicine composition for treating cardiovascular diseases | |
| CN102357210B (en) | Traditional Chinese medicine composition for curing facial acne | |
| CN102247502B (en) | Traditional Chinese medicine composition for treating breast cancer and preparation method thereof | |
| CN105106651A (en) | Traditional Chinese medicine for treating clear qi failing to ascend type nerve deafness | |
| CN101244194B (en) | Chinese medicine for treating scrofula disease | |
| CN102397375A (en) | Traditional Chinese medicine composition for treating gastrointestinal disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140604 |
|
| WD01 | Invention patent application deemed withdrawn after publication |